J&J to buy skin drug for $1.25B

Johnson & Johnson plans to buy the global rights to an experimental eczema therapy for $1.25 billion in cash, the company said May 28. 

The therapy is a bispecific antibody about to enter phase 2 studies targeting atopic dermatitis, a common inflammatory skin disease. Pending regulatory approval, J&J expects to acquire the drug candidate from Switzerland-based Numab Therapeutics in the second half of 2024.  

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like